Welcome
Support Centre
21 November 2008 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   UKCTG  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
Whole body hypothermia for the treatment of perinatal asphyxial encephalopathy
ISRCTN ISRCTN89547571
ClinicalTrials.gov identifier NCT00147030
Public title Whole body hypothermia for the treatment of perinatal asphyxial encephalopathy
Scientific title
Acronym TOBY (TOtal Body hYpothermia)
Serial number at source G0100126
Study hypothesis 1. To determine whether whole body cooling for 72 hours in term infants with perinatal asphyxial encephalopathy improves survival without neurological or neurodevelopmental disability at 18 months
2. To confirm the safety of prolonged whole body cooling in full term infants with perinatal asphyxial encephalopathy
Ethics approval Added as of 12/10/2007: Approved by London Multi-centre Research Ethics Committee (MREC) on 8th January 2002 (ref: MREC 00/02/73)
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Obstetrics and gynaecology
Participants - inclusion criteria Infants will be assessed sequentially by criteria A, B and C listed below:

A. Infants greater than or equal to 36 weeks gestation admitted to the Neonatal Intensive Care Unit (NICU) with ONE of the following:
1. Apgar score of less than five at ten minutes after birth
2. Continued need for resuscitation, including endotracheal or mask ventilation, at ten minutes after birth
3. Acidosis defined as either umbilical cord pH or any arterial pH within 60 minutes of birth less than pH 7.00
4. Base deficit greater than or equal to 16 mmol/l in umbilical cord blood sample or any blood sample within 60 minutes of birth (arterial or venous blood)

If the infant meets criteria A then assess for neurological abnormality (by trained study personnel):

B. Moderate to severe encephalopathy consisting of altered state of consciousness (lethargy, stupor or coma) and at least one or more of hypotonia, abnormal reflexes including oculomotor or pupillary abnormalities, an absent or weak suck or clinical seizures, as recorded by study personnel.

If the infant meets criteria A & B then assess by amplitude-integrated electroencephalography (aEEG) (read by trained study personnel):

C. At least 30 minutes duration of amplitude integrated EEG recording that shows abnormal background aEEG activity or seizures. There must be one of the following:
1. Normal background with some seizure activity
2. Moderately abnormal activity
3. Suppressed activity
4. Continuous seizure activity
Participants - exclusion criteria 1. Infants expected to be greater than 5.5 hours of age at the time of randomization
2. Major congenital abnormalities, such as diaphragmatic hernia requiring ventilation, or congenital abnormalities suggestive of chromosomal anomaly or other syndromes that include brain dysgenesis
Anticipated start date 01/09/2002
Anticipated end date 01/09/2008
Status of trial Completed
Patient information material Patient information can be found at: http://www.npeu.ox.ac.uk/TOBY/toby_downloads/toby_pil1.pdf
Target number of participants The original target was 236, which was achieved earlier than expected. Ethics approval for a revised target of 400 was obtained to continue recruitment. 325 babies actually recruited.
Interventions Full term infants will be randomized within six hours of birth to either a control group with the rectal temperature kept at 37 +/- 0.2 degrees celsius or to whole body cooling with the rectal temperature kept at 33.5 +/- 0.5 degrees celsius for 72 hours followed by slow rewarming.
Relevant physiological parameters will be monitored and outcome assessed at 18 months of age by survival and neurological and neurodevelopmental testing.

Recruitment closed at the end of the planned recruitment phase on 30/11/2006.
Primary outcome measure(s) The primary outcome for this trial is a combined endpoint: death in the first 18 months of life OR Severe neurodevelopmental disability.
Secondary outcome measure(s) Secondary outcome measures added as of 16/10/2007:
Short term (before discharge from hospital):
1. Intracranial haemorrhage
2. Persistent hypotension
3. Pulmonary haemorrhage
4. Pulmonary hypertension
5. Prolonged blood coagulation time
6. Culture proven sepsis
7. Necrotising enterocolitis
8. Cardiac arrhythmia
9. Thrombocytopenia
10. Major venous thrombosis
11. Renal failure treated with dialysis
12. Pneumonia
13. Pulmonary airleak
14. Duration of hospitalisation

Long term (at 18 months):
1. Mortality
2. Severe neurodevelopmental disability
3. Multiple handicap, defined as the presence of any two of the following in an infant:
3.1. Neuromotor disability (Level 3-5 on General Motor Function (GMF) Assessment Scale classification), mental delay (the Bayley Scales of Infant Development - Mental Development Indices (MDI) score less than 70), epilepsy, cortical visual impairment, sensorineural hearing loss
4. The Bayley Scales of Infant Development - Psychomotor Development Indices (PDI) score
5. Sensorineural hearing loss: greater than or equal to 40 dB
6. Epilepsy (defined as recurrent seizures beyond the neonatal period, requiring anticonvulsant therapy at the time of assessment)
7. Microcephaly (head circumference more than 2 standard deviations below the mean)
Sources of funding Medical Research Council (UK)
Trial website http://www.npeu.ox.ac.uk/TOBY/
Publications
Contact name Dr  Denis  Azzopardi
  Address Department of Paediatrics
ICSTM at Hammersmith
Du Cane Road
  City/town London
  Zip/Postcode W12 0NN
  Country United Kingdom
  Email
Sponsor Imperial College London (UK)
  Address Research Services, Medicine
Research Services Division
Faculty Building
South Kensington Campus
South Kensington
  City/town London
  Zip/Postcode SW7 2AZ
  Country United Kingdom
  Sponsor website: http://www.imperial.ac.uk/
Date applied 21/09/2000
Last edited 16/10/2007
Date ISRCTN assigned 21/09/2000
Submit your trial protocol Top studies in medical research Submit to Trials journal
© ISRCTN


BioMed Central